Fictious Healthcare Professional talking to fictious patient

Resources

We have created a range of expert lead video content and downloadable resources to support you and your advanced ovarian cancer patients who have been prescribed ZEJULA (niraparib).

ZEJULA is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

HCP, healthcare professional; MoA, mechanism of action; QoL, quality of life.

References

  1. ZEJULA Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

June 2023 | PM-GB-NRP-WCNT-210022 (V3.0)